A Phase 1 Multicenter, Open-label, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of MEDI6383 Alone and in Combination With MEDI4736 in Adult Subjects With Select Advanced Solid Tumors

Trial Profile

A Phase 1 Multicenter, Open-label, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of MEDI6383 Alone and in Combination With MEDI4736 in Adult Subjects With Select Advanced Solid Tumors

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 23 Jun 2017

At a glance

  • Drugs MEDI 6383 (Primary) ; Durvalumab
  • Indications Solid tumours
  • Focus Adverse reactions; First in man
  • Sponsors MedImmune
  • Most Recent Events

    • 20 Jun 2016 Planned number of patients changed from 224 to 39.
    • 20 Jun 2016 Status changed from recruiting to active, no longer recruiting.
    • 19 Feb 2016 According to ClinicalTrials.gov record, the treatment duration has been amended.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top